Published in Emerg Infect Dis on June 01, 2006
Comparison of serological and real-time PCR assays to diagnose Bordetella pertussis infection in 2007. J Clin Microbiol (2008) 1.51
Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. J Clin Microbiol (2009) 1.48
Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One (2008) 1.14
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol (2008) 1.02
Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis (2010) 0.98
Temporal trends in Bordetella pertussis populations, Denmark, 1949-2010. Emerg Infect Dis (2012) 0.94
Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine use. J Clin Microbiol (2011) 0.82
Investigating genome reduction of Bordetella pertussis using a multiplex PCR-based reverse line blot assay (mPCR/RLB). BMC Res Notes (2014) 0.76
Virulence Factors Variation Among Bordetella Pertussis Isolates in Iran. Int J Mol Cell Med (2015) 0.75
Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev (2005) 6.02
Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun (1998) 3.76
Pertussis of adults and infants. Lancet Infect Dis (2002) 2.95
Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology (1999) 2.09
Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol (2001) 2.02
Trends in pertussis among infants in the United States, 1980-1999. JAMA (2003) 1.94
Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun (2001) 1.64
Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg Infect Dis (2002) 1.58
Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine (2001) 1.42
Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect (2005) 1.36
Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol (2005) 1.28
Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J (2005) 1.19
Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine (2002) 1.11
Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol Infect (2004) 1.10
Strain variation among Bordetella pertussis isolates from Québec and Alberta provinces of Canada from 1985 to 1994. J Clin Microbiol (2003) 0.97
Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J (2007) 2.77
Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis (2009) 2.36
Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis (2010) 2.20
Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J (2005) 2.06
Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis (2007) 1.77
Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76
Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis (2011) 1.74
Bordetella holmesii DNA is not detected in nasopharyngeal swabs from Finnish and Dutch patients with suspected pertussis. J Med Microbiol (2006) 1.69
Significant finding of Bordetella holmesii DNA in nasopharyngeal samples from French patients with suspected pertussis. J Clin Microbiol (2011) 1.57
Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. J Infect Dis (2002) 1.57
Comparison of serological and real-time PCR assays to diagnose Bordetella pertussis infection in 2007. J Clin Microbiol (2008) 1.51
Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol (2012) 1.50
Multilocus sequence typing identifies evidence for recombination and two distinct lineages of Corynebacterium diphtheriae. J Clin Microbiol (2010) 1.47
Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis (2014) 1.43
Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines (2009) 1.38
Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect (2005) 1.36
Factors contributing to pertussis resurgence. Future Microbiol (2008) 1.35
Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J Infect Dis (2003) 1.29
New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis (2004) 1.29
Temporal analysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. Microbes Infect (2006) 1.29
Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol (2005) 1.28
Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics (2008) 1.26
Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26
The complete genome sequence of Corynebacterium pseudotuberculosis FRC41 isolated from a 12-year-old girl with necrotizing lymphadenitis reveals insights into gene-regulatory networks contributing to virulence. BMC Genomics (2010) 1.24
Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet (2006) 1.23
Diphtheria: a zoonotic disease in France? Vaccine (2009) 1.16
Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One (2008) 1.14
Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccin (2009) 1.14
Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine (2002) 1.11
Pertussis in Argentina and France. Vaccine (2006) 1.10
Bordetella holmesii and pertussis diagnosis. Pathology (2013) 1.07
Bordetella petrii infection with long-lasting persistence in human. Emerg Infect Dis (2011) 1.05
Rhinovirus infections in children: a retrospective and prospective hospital-based study. J Med Virol (2009) 1.05
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine (2006) 1.04
The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study. BMC Infect Dis (2012) 1.03
Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol (2008) 1.02
Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries. Infect Genet Evol (2011) 1.01
Real-time PCR measurement of persistence of Bordetella pertussis DNA in nasopharyngeal secretions during antibiotic treatment of young children with pertussis. J Clin Microbiol (2008) 0.99
Prevalence of Bordetella pertussis and Bordetella parapertussis infections in Tunisian hospitalized infants: results of a 4-year prospective study. Diagn Microbiol Infect Dis (2012) 0.99
Bordetella holmesii bacteremia in asplenic children: report of four cases initially misidentified as Acinetobacter lwoffii. J Clin Microbiol (2010) 0.99
Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis (2010) 0.98
Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains. J Clin Microbiol (2003) 0.98
Ultrasonography after the first febrile urinary tract infection in children. Eur J Pediatr (2006) 0.97
Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and toll-like receptors 2 and 4 in infants. PLoS One (2011) 0.96
Macrolide-resistant Bordetella pertussis infection in newborn girl, France. Emerg Infect Dis (2012) 0.96
Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis (2013) 0.95
Septic arthritis caused by Bordetella holmesii in an adolescent with chronic haemolytic anaemia. J Med Microbiol (2011) 0.94
Proficiency program for real-time PCR diagnosis of Bordetella pertussis infections in French hospital laboratories and at the French National Reference Center for Whooping Cough and other Bordetelloses. J Clin Microbiol (2009) 0.94
Nosocomial pertussis outbreak among adult patients and healthcare workers. Infect Control Hosp Epidemiol (2004) 0.94
Microarray analysis of response of Salmonella during infection of HLA-B27- transfected human macrophage-like U937 cells. BMC Genomics (2010) 0.93
SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One (2011) 0.93
Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol (2005) 0.93
Bordetella pertussis infection is common in nonvaccinated infants admitted for bronchiolitis. Pediatr Infect Dis J (2010) 0.92
Evaluation of four commercial real-time PCR assays for detection of Bordetella spp. in nasopharyngeal aspirates. J Clin Microbiol (2011) 0.92
Is the Sequenced Bordetella pertussis strain Tohama I representative of the species? J Clin Microbiol (2008) 0.92
Seroprevalence of antibodies to pertussis and diphtheria among healthy adults in China. J Infect (2011) 0.91
Bordetella bronchiseptica persists in the nasal cavities of mice and triggers early delivery of dendritic cells in the lymph nodes draining the lower and upper respiratory tract. Infect Immun (2003) 0.91
Genomic analysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas. Microbes Infect (2008) 0.90
Comparison of total white blood cell count and serum C-reactive protein levels in confirmed bacterial and viral infections. J Pediatr (2006) 0.90
Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis (2004) 0.89
Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis. J Clin Microbiol (2002) 0.89
Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine (2009) 0.89
Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine (2005) 0.88
Gene polymorphism in toll-like receptor 4: effect on antibody production and persistence after acellular pertussis vaccination during adolescence. J Infect Dis (2012) 0.88
Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations. Pediatr Infect Dis J (2005) 0.88
EUVAC.NET collaborative study: evaluation and standardisation of serology for diagnosis of pertussis. J Immunol Methods (2011) 0.87
Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine (2012) 0.87
Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines. Expert Rev Vaccines (2014) 0.87
Interactions between Bordetella pertussis and the complement inhibitor factor H. Mol Immunol (2010) 0.87